[Development of a Sensitive Enzyme-linked Immunosorbent Assay for Daptomycin]

Area of Science:

• Pharmacology
• Analytical Chemistry
• Infectious Diseases

Background:

• Daptomycin (DAP) is a vital antibiotic for treating methicillin-resistant Staphylococcus aureus (MRSA) infections.
• Conventional DAP assays present limitations in simplicity and sensitivity.
• DAP's potential side effects necessitate therapeutic drug monitoring.

Purpose of the Study:

• To develop a novel, highly sensitive, and specific enzyme-linked immunosorbent assay (ELISA) for daptomycin (DAP).
• To create an assay suitable for pharmacokinetic studies and therapeutic drug monitoring of DAP.

Main Methods:

• Production of anti-DAP antibodies via mouse immunization with a conjugated antigen.
• Enzymatic labeling of DAP with horseradish peroxidase using specific coupling agents.
• Development and validation of the ELISA using human serum samples.

Main Results:

• The developed ELISA demonstrated high sensitivity and specificity for DAP detection.
• The assay exhibited a linear detection range from 0.3 to 72.9 ng/mL.
• A limit of quantification of approximately 0.3 ng/mL was achieved.

Conclusions:

• The novel ELISA offers a simpler and more sensitive method for DAP quantification compared to existing assays.
• This assay is a valuable tool for pharmacokinetic studies and therapeutic drug monitoring of DAP.
• Improved DAP monitoring can potentially enhance patient outcomes and treatment efficacy.